© 2022 BioMarin. All rights reserved.

We seek the big effect.

By strategically focusing on rare disorders with de­fined genetic defects, we strive to develop innovative therapies that are ­first- or best-in-class.

Molecule
Phase (Preclinical, Phase 1, Phase 2, Phase 3, BLA/NDA/MAA, Approval)
  • Valoctocogene Roxaparvovec (BMN 270) AAV-Factor VIII
    Phase 3
    Target Indication

    Valoctocogene roxaparvovec is an investigational AAV5 gene therapy under regulatory review for the treatment of severe hemophilia A.

    Learn More about Valoctocogene Roxaparvovec
  • BMN 331
    Phase 1
    Target Indication

    BMN 331 is an investigational AAV5-mediated gene therapy designed to address hereditary angioedema (HAE)

    Learn More about BMN 331 AAV
  • BMN 307
    Phase 1
    Target Indication

    BMN 307 is an investigational AAV5-mediated gene therapy designed to address phenylketonuria (PKU)

    Learn More
  • BMN 255
    Phase 1
    Target Indication

    BMN 255 is an investigational small molecule designed to address hyperoxaluria

  • BMN 349
    Preclinical
    Target Indication

    BMN 349 is an investigational small molecule designed to address alpha-1 antitrypsin deficiency (AATD)

  • BMN 351
    Preclinical
    Target Indication

    BMN 351 is an investigational antisense oligonucleotide (ASO) designed to address exon-51 skip-amenable Duchenne muscular dystrophy (DMD)

  • BMN 293 (DINA-001)
    Preclinical
    Description/Indication

    BMN 293 is an investigational gene therapy designed to address MYBPC3 hypertrophic cardiomyopathy

Image: BioMarin scientists
Clinical Trials

More than 20 years of proven clinical success.

Our thoughtful approach to clinical trial design enables us to move fast and efficiently while protecting the safety of our patients.

Learn More about our clinical trials